Literature DB >> 24919931

Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling.

Angelica L Quartino1, Mats O Karlsson, Henrik Lindman, Lena E Friberg.   

Abstract

PURPOSE: Neutropenia is a severe adverse-event of chemotherapeutics. Neutrophils (ANC) are mainly regulated by granulocyte colony stimulating factor (G-CSF). The aim was to characterize the dynamics between endogenous G-CSF and ANC over time following chemotherapy.
METHODS: Endogenous G-CSF and ANC were monitored in forty-nine breast cancer patients treated with sequential adjuvant 5-fluorouracil-epirubicin-cyclophosphamide and docetaxel.
RESULTS: During treatment courses ANC was transiently decreased and was reflected in an endogenous G-CSF increase, which was well described by a semi-mechanistic model including control mechanisms; when G-CSF concentrations increased the proliferation rate increased and the bone maturation time reduced for ANC. Subsequently, ANC in the circulation increased leading to increased elimination of G-CSF. Additionally, a non-specific elimination for G-CSF was quantified. The ANC-dependent elimination contributed to 97% at baseline and 49% at an ANC of 0.1 · 10(9)/L to the total G-CSF elimination.
CONCLUSION: The integrated G-CSF-myelosuppression model captured the initial rise in endogenous G-CSF following chemotherapy-induced neutropenia and the return to baseline of G-CSF and ANC. The model supported the self-regulatory properties of the system and may be a useful tool for further characterization of the biological system and in optimization of chemotherapy treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24919931     DOI: 10.1007/s11095-014-1429-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  50 in total

1.  Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics.

Authors:  Donald E Mager; Sheren X Lin; Robert A Blum; Christian D Lates; William J Jusko
Journal:  J Clin Pharmacol       Date:  2003-11       Impact factor: 3.126

2.  Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

Authors:  M Colleoni; K Price; M Castiglione-Gertsch; A Goldhirsch; A Coates; J Lindtner; J Collins; R D Gelber; B Thürlimann; C M Rudenstam
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

3.  Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Authors:  Mélanie L Pastor; Céline M Laffont; Laurence Gladieff; Antonin Schmitt; Etienne Chatelut; Didier Concordet
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

4.  Effects of a single, large, intravenous injection of dexamethasone.

Authors:  A W Czerwinski; A B Czerwinski; T L Whitsett; M L Clark
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

5.  Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells.

Authors:  T Kuwabara; S Kobayashi; Y Sugiyama
Journal:  Am J Physiol       Date:  1996-07

6.  Serum granulocyte colony-stimulating factor kinetics in children receiving intense chemotherapy with or without stem cell support.

Authors:  S Saito; Y Kawano; T Watanabe; Y Okamoto; T Abe; Y Kurada; Y Takaue
Journal:  J Hematother       Date:  1999-06

Review 7.  Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor.

Authors:  T Kuwabara; S Kobayashi; Y Sugiyama
Journal:  Drug Metab Rev       Date:  1996-11       Impact factor: 4.518

8.  Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children.

Authors:  N Stute; V M Santana; J H Rodman; M J Schell; J N Ihle; W E Evans
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

9.  Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.

Authors:  Emma K Hansson; Johan E Wallin; Henrik Lindman; Marie Sandström; Mats O Karlsson; Lena E Friberg
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-14       Impact factor: 3.333

10.  Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

Authors:  Jeffrey Crawford; David C Dale; Nicole M Kuderer; Eva Culakova; Marek S Poniewierski; Debra Wolff; Gary H Lyman
Journal:  J Natl Compr Canc Netw       Date:  2008-02       Impact factor: 11.908

View more
  22 in total

1.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Authors:  Wenbo Chen; Britton Boras; Tae Sung; Yanke Yu; Jenny Zheng; Diane Wang; Wenyue Hu; Mary E Spilker; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-03-11       Impact factor: 2.745

2.  Mathematical analysis and drug exposure evaluation of pharmacokinetic models with endogenous production and simultaneous first-order and Michaelis-Menten elimination: the case of single dose.

Authors:  Xiaotian Wu; Fahima Nekka; Jun Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-09       Impact factor: 2.745

3.  A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.

Authors:  Ari Brekkan; Luis Lopez-Lazaro; Gunnar Yngman; Elodie L Plan; Chayan Acharya; Andrew C Hooker; Suresh Kankanwadi; Mats O Karlsson
Journal:  AAPS J       Date:  2018-08-15       Impact factor: 4.009

4.  The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Authors:  Ida Netterberg; Mats O Karlsson; Elisabet I Nielsen; Angelica L Quartino; Henrik Lindman; Lena E Friberg
Journal:  Br J Clin Pharmacol       Date:  2018-01-18       Impact factor: 4.335

5.  A cell-level model of pharmacodynamics-mediated drug disposition.

Authors:  Wojciech Krzyzanski; John M Harrold; Liviawati S Wu; Juan Jose Perez-Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-09       Impact factor: 2.745

6.  Transit and lifespan in neutrophil production: implications for drug intervention.

Authors:  Daniel Câmara De Souza; Morgan Craig; Tyler Cassidy; Jun Li; Fahima Nekka; Jacques Bélair; Antony R Humphries
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-13       Impact factor: 2.745

7.  Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.

Authors:  Murad Melhem; Isabelle Delor; Juan Jose Pérez-Ruixo; John Harrold; Andrew Chow; Liviawati Wu; Philippe Jacqmin
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

8.  Structural identifiability for mathematical pharmacology: models of myelosuppression.

Authors:  Neil D Evans; S Y Amy Cheung; James W T Yates
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-02       Impact factor: 2.745

9.  Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.

Authors:  Pauline Macaire; Justine Paris; Julie Vincent; François Ghiringhelli; Leïla Bengrine-Lefevre; Antonin Schmitt
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

10.  Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.

Authors:  Sachi Morita; Toyone Kikumori; Nobuyuki Tsunoda; Takahiro Inaishi; Yayoi Adachi; Akiko Ota; Masahiro Shibata; Ayumu Matsuoka; Kenichi Nakanishi; Dai Takeuchi; Takefumi Mizutani; Tomoya Shimokata; Hironori Hayashi; Osamu Maeda; Yuichi Ando
Journal:  Int J Clin Oncol       Date:  2017-08-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.